摘要：Background:Total mesorectum excision(TME)is considered the standard surgical procedure for rectal-cancer *** TME(taTME)is a new procedure to treat low rectal *** published studies have proven that taTME can provide a better-quality resected specimen in low-rectal-cancer patients in comparison to the transabdominal procedure,yet long-term outcomes must be *** designed this non-inferiority trial(TaLaR trial)to compare short-term and long-term outcomes between taTME and laparoscopic TME(lapTME)for rectal ***:The TaLaR trial is a phase III open-labeled multicenter randomized-controlled *** who are diagnosed with rectal cancer with no more than T3N2 stage,and with the tumor location below the peritoneal reflection by magnetic resonance imaging scan,digital rectal examination,or colonoscopy,qualify for this *** calculating,a total of 1,114 patients(557 per group)will be randomly allocated to either the taTME or the lapTME *** endpoints are the 3-year disease-free survival(DFS)rate and the 5-year overall survival(OS)*** endpoints include specimen quality,perioperative results,pelvic and anal function,and quality of ***:The TaLaR trial is expected to clarify whether taTME can achieve comparable oncological outcomes,as well as improve specimen quality and recovery conditions in rectal-cancer patients compared with lapTME.